CD4+ Th1 to the rescue in HER-2+ breast cancer. (3rd October 2019)

• Record Type: Journal Article
• Authors: Lowenfeld, Lea; Xu, Shuwen; Czerniecki, Brian J.
• Is Part Of: Oncoimmunology. Volume 8:Number 10(2019)
• Publication Date: 2019-10-03
• Subjects: HER2 -- CD8+ T-cells -- MHC class-I -- CD4+ T-cells -- IFNγ -- TNFα -- monoclonal antibodies -- trastuzumab -- pertuzumab; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2015.1078062
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: HER2 overexpression leads to downregulation of MHC class-I. CD4 + Th1 cytokines, IFNγ and TNFα, and monoclonal antibodies, trastuzumab and pertuzumab, restore MHC class-I expression, and enable CD8 + recognition and cytolysis. Restoration of the anti-HER2 CD4 + Th1 immune response in combination with HER2 targeted therapy appear to be critical to successful anti-HER2 CD8 + immunotherapy.